Abcellera Biologics Inc (ABCL) Key Ratios
$11.57
As on 03-Sep-2026 16:19EDT
Market cap
$3,678 Mln
Revenue (TTM)
$66 Mln
P/E Ratio
--
P/B Ratio
4.5
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -51.29 | -76.29 | 101.28 | -23.04 | -31.77 |
| EBIT | -19.03 | -28.48 | 23.59 | -165.32 | -191.36 |
| Net Profit | -28.41 | -59.61 | 0.61 | -66.00 | -195.19 |
| EPS | -27.36 | -55.93 | 2.53 | -145.79 | -194.77 |
| Book Value | -- | -- | -9.71 | -7.53 | 4.54 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-25 | Dec-24 |
| EBIT-Margin
| -622.48 | -367.58 | -304.58 | -236.39 | -1,044.45 |
| Net Margin
| -- | 11.41 | -248.83 | -- | -- |
| Return on equity
| -13.83 | -5.54 | -17.68 | -14.47 | -14.75 |
| Return on Capital
| -12.83 | -5.08 | -- | -13.12 | -13.85 |
| Return on Assets
| -10.63 | -4.20 | -11.64 | -10.78 | -11.43 |
| Debt to Equity (x)
| -- | -- | 0.00 | 0.15 | 0.06 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Abcellera Biologics Inc (ABCL)
|
--
|
-13.12
|
-13.85
|
-11.50
|
13.31
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
-17.68
Lower than Peers by 1.70
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Abcellera Biologics Inc (ABCL)
|
-17.68
|
-14.47
|
-14.75
|
-12.27
|
14.03
|
|
Peer Median
|
-15.98
|
--
|
--
|
--
|
--
|
ROA
-11.64
Higher than Peers by 0.21
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Abcellera Biologics Inc (ABCL)
|
-11.64
|
-10.78
|
-11.43
|
-9.67
|
11.09
|
|
Peer Median
|
-11.85
|
--
|
--
|
--
|
--
|
EBIT Margin
-304.58
Lower than Peers by 277.52
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Abcellera Biologics Inc (ABCL)
|
-304.58
|
-236.39
|
-1,044.45
|
-586.59
|
46.78
|
|
Peer Median
|
-27.06
|
--
|
--
|
--
|
--
|
Net Margin
-248.83
Lower than Peers by 216.14
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Abcellera Biologics Inc (ABCL)
|
-248.83
|
-194.88
|
-564.83
|
-385.00
|
31.20
|
|
Peer Median
|
-32.69
|
--
|
--
|
--
|
--
|
Cash Profit Margin
0.00
Lower than Peers by 0.00
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Abcellera Biologics Inc (ABCL)
|
0.00
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.00
|
--
|
--
|
--
|
--
|
Revenue Growth
101.28
Higher than Peers by 67.31
Year on year growth in net sales
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Abcellera Biologics Inc (ABCL)
|
101.28
|
1.61
|
-0.24
|
-0.92
|
40.81
|
|
Peer Median
|
33.97
|
--
|
--
|
--
|
--
|
EBIT Growth
23.59
Higher than Peers by 48.85
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Abcellera Biologics Inc (ABCL)
|
23.59
|
41.03
|
-35.01
|
-198.23
|
11,444.74
|
|
Peer Median
|
-25.26
|
--
|
--
|
--
|
--
|
Net Profit Growth
0.61
Higher than Peers by 22.19
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Abcellera Biologics Inc (ABCL)
|
0.61
|
10.10
|
-11.24
|
-192.35
|
7,270.55
|
|
Peer Median
|
-21.58
|
--
|
--
|
--
|
--
|
EPS Growth
2.53
Higher than Peers by 8.70
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Abcellera Biologics Inc (ABCL)
|
2.53
|
0.11
|
-0.10
|
-1.96
|
75.94
|
|
Peer Median
|
-6.17
|
--
|
--
|
--
|
--
|
Book Value Growth
-13.08
Lower than Peers by 10.19
Year on year growth in book value per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Abcellera Biologics Inc (ABCL)
|
-13.08
|
--
|
--
|
--
|
--
|
|
Peer Median
|
-2.89
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
--
--
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Abcellera Biologics Inc (ABCL)
|
--
|
0.15
|
0.06
|
0.07
|
0.07
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
0.01
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Abcellera Biologics Inc (ABCL)
|
0.01
|
0.01
|
0.00
|
0.01
|
0.00
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
12.77
Higher than Peers by 3.66
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Abcellera Biologics Inc (ABCL)
|
12.77
|
11.32
|
9.81
|
7.33
|
8.67
|
|
Peer Median
|
9.11
|
--
|
--
|
--
|
--
|
Quick Ratio
12.63
Higher than Peers by 3.52
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Abcellera Biologics Inc (ABCL)
|
12.63
|
11.23
|
9.81
|
7.32
|
8.65
|
|
Peer Median
|
9.11
|
--
|
--
|
--
|
--
|
Interest Coverage
-11.19
Lower than Peers by 11.91
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Abcellera Biologics Inc (ABCL)
|
-11.19
|
--
|
--
|
--
|
56.13
|
|
Peer Median
|
0.72
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
144.21
Higher than Peers by 121.45
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Abcellera Biologics Inc (ABCL)
|
144.21
|
204.18
|
319.53
|
169.31
|
21.30
|
|
Peer Median
|
22.75
|
--
|
--
|
--
|
--
|
Asset Turnover
0.05
Lower than Peers by 0.01
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Abcellera Biologics Inc (ABCL)
|
0.05
|
0.06
|
0.02
|
0.03
|
0.34
|
|
Peer Median
|
0.06
|
--
|
--
|
--
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Abcellera Biologics Inc (ABCL)
|
--
|
596.85
|
991.33
|
805.86
|
104.69
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Abcellera Biologics Inc (ABCL)
|
--
|
40.15
|
2.08
|
15.60
|
8.81
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Abcellera Biologics Inc (ABCL)
|
--
|
377.52
|
112.70
|
238.45
|
81.78
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Abcellera Biologics Inc (ABCL)
|
--
|
259.48
|
880.71
|
583.02
|
31.71
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
--
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Abcellera Biologics Inc (ABCL)
|
--
|
-6.98
|
-5.30
|
-11.35
|
19.25
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Price / Book Value
4.48
Lower than Peers by 0.35
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Abcellera Biologics Inc (ABCL)
|
4.48
|
1.06
|
0.82
|
1.44
|
2.47
|
|
Peer Median
|
4.83
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Abcellera Biologics Inc (ABCL)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
5.30
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Abcellera Biologics Inc (ABCL)
|
5.30
|
-4.24
|
-1.48
|
-5.09
|
8.64
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
3,678
Higher than Peers by 3,461
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Abcellera Biologics Inc (ABCL)
|
3,678
|
--
|
--
|
--
|
--
|
|
Peer Median
|
217
|
--
|
--
|
--
|
--
|